Sai Life Sciences to boost biology capabilities at its integrated R&D campus

The CRDMO will expand in vitro and in vivo biology services, DMPK and toxicology capabilities.

The new facility will house expanded in vitro and in vivo biology services, drug metabolism and pharmacokinetics (DMPK) and toxicology capabilities with the first set of labs scheduled to open in March 2021.

According to the company's CEO & Managing Director, Krishna Kanumuri, the company aspires to deliver more than 100 development candidates for its innovator partners by 2025.

"Our growing discovery biology team co-located with our teams in medicinal chemistry, process development, process engineering and scale-up will enable us to accelerate our clients’ discovery programs through rapid turnaround times and shorter decision-making cycles,” said Kanumuri.

Sai Life Sciences has been steadily growing its biology capabilities to complement its foundation in medicinal chemistry, DMPK and toxicology for supporting its customers across the entire drug discovery journey from target identification and validation to IND.

Last year, the company opened its first international R&D facility with a biology lab in Boston, US, which offers local start-up and biotech companies biology services to address exploratory and custom biology needs.